Brünnert, D.; Seupel, R.; Goyal, P.; Bach, M.; Schraud, H.; Kirner, S.; Köster, E.; Feineis, D.; Bargou, R.C.; Schlosser, A.;
et al. Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate. Pharmaceuticals 2023, 16, 1181.
https://doi.org/10.3390/ph16081181
AMA Style
Brünnert D, Seupel R, Goyal P, Bach M, Schraud H, Kirner S, Köster E, Feineis D, Bargou RC, Schlosser A,
et al. Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate. Pharmaceuticals. 2023; 16(8):1181.
https://doi.org/10.3390/ph16081181
Chicago/Turabian Style
Brünnert, Daniela, Raina Seupel, Pankaj Goyal, Matthias Bach, Heike Schraud, Stefanie Kirner, Eva Köster, Doris Feineis, Ralf C. Bargou, Andreas Schlosser,
and et al. 2023. "Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate" Pharmaceuticals 16, no. 8: 1181.
https://doi.org/10.3390/ph16081181
APA Style
Brünnert, D., Seupel, R., Goyal, P., Bach, M., Schraud, H., Kirner, S., Köster, E., Feineis, D., Bargou, R. C., Schlosser, A., Bringmann, G., & Chatterjee, M.
(2023). Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate. Pharmaceuticals, 16(8), 1181.
https://doi.org/10.3390/ph16081181